BAIPC will work to deploy a series of solutions to change the future direction of BioSig
WESTPORT, Conn., April 4, 2024 (Globe Newswire) — Biosig Technologies Co., Ltd. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company that provides unprecedented accuracy and precision for visualization of intracardiac signals, today announced that Bridge Associates International Pharmaceutical Consulting ( announced the appointment of BAIPC.
BAIPC will work to implement a suite of solutions to transform BioSig's future direction with additional strategies including operations, staff, systems and processes. Alternative policies and procedures may be evaluated and initiated to restabilize operating and fiscal deficits and transform them into a restructured recovery. BAIPC has an outreach support system led by Anthony Amato with over 35 years of experience. Mr. Amato currently serves as his CEO of InQuest Science and his BAIPC.
About BioSig Technologies, Inc.
biosig technologies is a medical technology company focused on deciphering the body's electrical signals, including heart rhythm. Leveraging a first-of-its-kind combination of hardware and software, it delivers unprecedented cardiac signal clarity and eliminates reliance on “mixed signals” and “reading between the lines.” Our platform technology tackles some of the healthcare industry's biggest challenges: saving time, saving money and saving lives.
The company's product, the PURE EP™ platform, is an FDA 510(k)-certified non-invasive Class II device that provides superior real-time signal visualization to help physicians increase procedure efficiency and effectiveness. Enables highly targeted cardiac ablation procedures to be performed.
An estimated 14.4 million Americans suffer from cardiac arrhythmias, and the cardiac ablation market is valued at $3.5 billion in 2022, with an expected growth rate of 13.5%.1
Forward-looking statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” and “expects.” “anticipate,” “anticipate,” “anticipate,” “estimate,” “target,” “believe,” “hope,” “could,” or similar words . Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to a variety of known and unknown risks and uncertainties, many of which are beyond the Company's control. and cannot be predicted or quantified and actual results may vary. may differ materially from that expressed or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to, risks and uncertainties related to: (i) Biosig's ability to regain compliance with and satisfy the continued listing requirements of the Nasdaq Capital Market to maintain the listing of its common stock; (ii) the Company's cost reduction plans and related headcount reductions or other cost reduction actions fail to achieve the targeted 50% reduction in cash burn; (iii) the geographic, social and economic impact of the pandemic or global health issues on BioSig's ability to conduct business and obtain financing as needed in the future; (iv) BioSig's inability to manufacture its products and product candidates on a commercial scale, either by itself or in collaboration with third parties; (v) difficulty in obtaining financing on commercially reasonable terms; (vi) changes in the magnitude and nature of BioSig's competition; (vii) loss of one or more key executives or scientists; (viii) difficulties in obtaining regulatory approval to market BioSig's products and product candidates; For additional risks, uncertainties and other important factors that could cause BioSig's actual results to differ from those contained in the forward-looking statements, please contact the Securities and Exchange Commission (“SEC”). See Biosig's filing. Section titled “Risk Factors” of BioSig's Quarterly Report on Form 10-Q filed with the SEC on November 14, 2023. Investors and securityholders are encouraged to read these documents free of charge on the SEC's website at http://www. Second Government The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
1 Cardiac ablation market. (December 2022). Global market insights. https://www.gminsights.com/industry-analysis/cardiac-ablation
CONTACT: Contact: Todd Adler BioSig Technologies, Inc. Investor Relations 55 Greens Farms Westport, CT 06880 tadler@biosigtech.com 203-409-5444, x104
